Billiontoone Inc (BLLN) Stock Forecast & Price Target

BillionToOne is attractive because its QCT platform and single-molecule detection create a durable accuracy advantage across prenatal and oncology testing, supporting differentiated products like UNITY, Northstar Select, and Northstar Response in markets still early in penetration. The company has combined that technology edge with unusually strong execution, posting Q1'26 revenue of $108.4M (+84% Y/Y), 73% gross margin, 16% GAAP operating margin, 24% adjusted EBITDA margin, and $537M of cash, while maintaining profitability seven years post launch. Its outlook is further reinforced by expanding payer coverage to ~300M lives, ~15% prenatal share, and a catalyst-rich pipeline including UNITY Confirm and a tumor-naïve MRD launch, which could extend growth while preserving financial discipline.

BillionToOne is facing a weaker fundamental setup as the model was cut across 2026 to 2028, with 2028 revenue reduced to $780M from $830M and product revenue per test lowered to $584 from $605, while operating expenses were raised to $438M. The firm still expects growth, but margin pressure is evident as gross margin slips to 70% in 2028 and expenses rise faster than revenue, implying less operating leverage than previously assumed. Its outlook is further burdened by execution and competitive risks in prenatal testing, therapy selection, MRD and early detection, alongside reimbursement, billing complexity, litigation, and key-person dependence that could impair commercialization and cash generation.